Advanced Health Intelligence (AHI) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Advanced Health Intelligence in May 2026.
Advanced Health Intelligence Limited is an Australia-based company that provides biometric-derived digital healthcare solutions. The Company’s products include Biometric Health Assessment (BHA), FaceScan, and BodyScan. Its BHA delivers preventative healthcare measures and refines risk stratification across populations. Its comprehensive insights cover a range of health vitals and risk predictions, allowing its partners to guide individuals into personalized stepped-care pathways. This includes connecting high-risk individuals to traditional primary care, telehealth, or e-health programs. FaceScan estimates vital signs and predicts the risk of chronic disease on a smartphone or Web browser. FaceScan provides estimated readings on heart rate, respiration rate, blood pressure and more in 30 seconds or less. BodyScan is optimized to run on-device using only a smartphone, to deliver accurate body dimension and composition estimates in 60 seconds or less.
Stock Performance Snapshot
Analyst Rating
Analysts recommend holding Advanced Health Intelligence Ltd's stock with a target price of $7.92.
Financial Health
Advanced Health Intelligence Ltd has low revenue and cash flow, indicating potential financial challenges.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring AHI
AI Governance And Compliance Technology
This carefully selected group of stocks focuses on companies helping businesses navigate the complex world of AI regulations. As tensions rise between tech giants and regulators, these companies provide the essential tools and services organizations need to stay compliant and avoid costly penalties.
Published: July 21, 2025
Explore BasketAI Compliance Divergence: RegTech Solutions for EU Standards
This carefully selected group of stocks represents companies at the forefront of AI governance and compliance solutions. Our professional analysts have identified these opportunities emerging from the regulatory divide between tech giants like Microsoft and Meta, as businesses increasingly need specialized help to navigate complex AI rules.
Published: July 20, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.